Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 34Neoplasm Metastasis 5Breast Neoplasms 4Prostate Carcinoma Metastatic to the Bone 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Hormone Refractory Prostate Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Lung Neoplasms 1Castrate-Resistant Prostate Cancer 1Bone Metastatic Castration-resistant Prostate Cancer 1Bone Metastases 1Bone Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Docetaxel 4radium Ra 223 dichloride 2Prednisone 2sargramostim 1gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1PE regimen 1Mycobacterium w vaccine 1Injections 1Everolimus 1Etoposide 1Denosumab 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hormone Refractory Prostate Cancer × radium Ra 223 dichloride × Clear all
NCT00699751 2026-02-23

ALSYMPCA

Bayer

Phase 3 Completed
921 enrolled 43 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

Bayer

Phase 2 Completed
100 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡